Mass Tort brief
Israeli Pharma Facing High-Stakes US Liability Pressures
Teva and Taro navigate a mounting wave of expensive US antitrust settlements and product defect lawsuits.
Mass Tort
Teva's legacy contraceptive liabilities keep expanding — 4,000 active lawsuits mean the TASE-listed drugmaker faces multi-year financial drains that overshadow its previous defense trial win.
BackgroundThe copper Paragard T 380A is a non-hormonal intrauterine contraceptive designed to prevent pregnancy for up to 10 years. Device breakage during removal has triggered thousands of injuries, leaving Teva liable for older devices sold before it divested the brand in 2017.
- The centralized multi-district litigation continues to expand under Judge Leigh Martin May in Georgia, forcing Teva to sustain high legal defense spending despite its previous efforts to dismiss the claims.
- New transfer cases like Leah Pepper v. Teva USA expand the active docket, maintaining pressure on the pharmaceutical firm's balance sheet and litigation reserve estimates.
- A crucial defense verdict in the first federal bellwether trial provided temporary relief, but postponed subsequent trials now delay any final clarity on Teva's long-term financial exposure.
Mass Tort
Taro's $200M class-action settlement removes a decade-old generic price-fixing liability — freeing up capital helps the Haifa-based drugmaker focus on expanding its core pharmaceutical exports.
BackgroundTaro is a major producer of generic topical creams and cardiovascular treatments exported from its manufacturing hub in northern Israel. The consolidated US litigation accused multiple drugmakers of colluding to inflate generic drug prices, triggering regulatory probes and class actions.
- The final judicial order resolves all outstanding end-payer class-action claims against Taro, allowing the company to redirect millions of dollars from legal defense funds into its research and development pipeline.
- The resolution ends allegations first filed in 2016 without any admission of wrongdoing, enabling Taro to restore its corporate reputation among major US healthcare distributors.
- Clearing this massive litigation overhang stabilizes Taro's financial projections, offering relief to its parent company Sun Pharma and local Israeli operational stakeholders.
Mass Tort
Teva's $35M inhaler settlement resolves another patent-abuse dispute — clearing these legacy antitrust claims protects cash reserves from the far larger threats of ongoing trial litigation.
BackgroundQVAR is a branded steroid inhaler designed to prevent asthma attacks by reducing airway inflammation. US buyers sued Teva for allegedly engaging in patent-abuse strategies to block competition, a common antitrust issue for generic manufacturers transitioning to proprietary drugs.
- The settlement offers pro-rata cash payouts to commercial and individual buyers in 42 states, helping Teva avert the unpredictable costs of an antitrust trial.
- Eligible consumers and health insurers have until the July 31, 2026 deadline to file claims, which will begin distributing the $35 million settlement fund.
- The payout represents another legacy litigation drain on Teva's cash reserves, although resolving these disputes incrementally reduces the firm's overall risk profile.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.